Survodutide

Survodutide is an investigational once-weekly peptide from Boehringer Ingelheim that flips two metabolic switches at once — the GLP-1 receptor and the glucagon receptor. In a phase 3 human trial, the 6.0 mg group lost an average of 13.0% of body weight at 76 weeks versus 5.4% with placebo, and a separate phase 3 trial showed reduced liver fat in MASLD. It is not FDA-approved yet; phase 3 trials are completed or ongoing across the obesity, cardiovascular-safety, and MASH programs.

What is survodutide?

Survodutide (development code BI 456906) is a synthetic peptide being developed by Boehringer Ingelheim as a weekly injection for obesity and for fatty-liver disease. What makes survodutide different from the household GLP-1 drugs is that it is a dual agonist: it activates the GLP-1 receptor and the glucagon receptor. If you’re reading this, odds are you’ve already lost the plot on the alphabet soup of “-tides” and just want to know where this one sits — so here’s the short version: survodutide is in the same family as semaglutide and tirzepatide, it’s one of the metabolic peptides on our GLP-1 & metabolic hub, and it is further along than almost any research peptide on this site, with real phase 2 and phase 3 human data rather than rat studies.

How does survodutide work?

Survodutide works by pressing two hormone buttons that normally push in different directions. The GLP-1 receptor is the appetite side: switching it on is like turning down the volume on hunger and slowing how fast the stomach empties, so you feel full sooner and longer — the same mechanism behind semaglutide. The glucagon receptor is the energy-and-liver side: glucagon nudges the body to burn stored fuel and pull fat out of the liver. On its own glucagon would raise blood sugar, but paired with a strong GLP-1 signal that keeps sugar in check, the glucagon arm is meant to add extra fat-burning and direct liver-fat clearance on top of appetite suppression. Think of it as one pedal that eases you off eating while a second pedal quietly raises the rate you spend energy. That two-pedal design is exactly why survodutide is being tested so hard in fatty-liver disease, where liver fat is the core problem.

What does the research show?

Survodutide has genuine human randomized-controlled-trial evidence, which is rare in the peptide world and is why it grades Human RCT rather than animal-only. In the phase 3 SYNCHRONIZE-1 randomized, placebo-controlled obesity trial, the 6.0 mg group lost an average of 13.0% of body weight at 76 weeks versus 5.4% with placebo (PubMed). In a separate phase 2 trial in people with MASH (the fatty-liver disease formerly called NASH), significantly more people on survodutide had their liver disease improve without their fibrosis worsening than on placebo (NCT04771273). A phase 3 trial in at-risk MASLD also found that 68.5% of survodutide-treated participants had at least a 30% reduction in liver fat at 48 weeks versus 28.6% with placebo under the treatment-regimen estimand (Nature Medicine). The honest frame here is momentum, not doubt: survodutide has now moved into a full phase 3 program — SYNCHRONIZE for obesity (NCT06066515) and LIVERAGE for MASH — plus an active, no-longer-recruiting cardiovascular-safety trial (NCT06077864) whose results haven’t been reported yet. In other words, survodutide’s confirmatory readouts are still ahead of it, not behind it.

What the community reports

Because survodutide isn’t approved or sold, there’s far less real-world chatter about it than about semaglutide or tirzepatide, and what exists is speculation about trial results and comparisons to other incretin drugs rather than firsthand use. Treat any “I ran survodutide” post with real caution: this compound is not on the research- peptide market the way BPC-157 is, so an online product claiming to be survodutide is unverified and could be anything. These community threads are anecdotal and tell you about interest, not about safety or how well it works — for that, the phase 2 and phase 3 trials above are the only trustworthy source.

Is survodutide safe? Side effects

Survodutide’s safety picture is unusually well-defined for a peptide because it has been tested in real human trials, not just rodents. The most common side effects were gastrointestinal — nausea, vomiting, diarrhea and constipation — the same profile as other incretin drugs, and mostly mild to moderate. These effects were clearly tied to how quickly the dose was raised, and slowing the titration reduced them; some participants at higher doses still stopped treatment because of them. Decreased appetite is expected and is part of how survodutide works rather than a true adverse event. What isn’t settled yet is the long game: long-term safety and, importantly, cardiovascular outcomes are exactly what the phase 3 program and the active, no-longer-recruiting cardiovascular-safety trial are designed to answer, and those data aren’t in. As with the whole incretin class, the sensible reading is that the common side effects are known and manageable, while the multi-year safety story is still being written.

FDA & legal status (2026)

Survodutide is not FDA-approved for any use as of 2026, and it is not a dietary supplement. It is an investigational drug in phase 3 development at Boehringer Ingelheim, which means the only legitimate way to receive survodutide is by enrolling in a registered clinical trial. It is not legally sold for human consumption, and — unlike the classic research peptides — it isn’t widely offered on the research-chemical market either, so anything advertised online as “survodutide” should be treated as unverified. Because status can change quickly once a phase 3 program reads out, treat this as dated to mid-2026 and re-check the full dated breakdown in the regulatory block below.

How is survodutide dosed in research?

Survodutide is given as a once-weekly subcutaneous injection, and in trials it is started low and titrated upward over weeks specifically to blunt the early nausea. The phase 2 obesity trial escalated doses up to roughly 4.8 mg once weekly (NCT04667377), and the phase 3 formulation work has focused on delivery via a pre-filled syringe or pen-style injector rather than a vial you reconstitute yourself. That’s an important practical difference from research peptides: survodutide isn’t a freeze-dried powder the community mixes at home, so the reconstitution calculator and mixing tools that matter for BPC-157 aren’t really the right frame here. These are doses reported in trials, not a protocol — survodutide is investigational, and there is no validated at-home regimen.

Survodutide vs the other GLP-1 drugs

Survodutide’s whole pitch is the glucagon receptor. Semaglutide is a single GLP-1 agonist; tirzepatide is a GLP-1/GIP dual agonist; retatrutide is a GLP-1/GIP/glucagon triple agonist. Survodutide sits in its own spot: GLP-1 plus glucagon, no GIP. That glucagon arm is why it’s being pushed so hard in fatty-liver disease, where pulling fat out of the liver is the goal. On raw weight-loss numbers the approved drugs currently have the longer track record — if you want the head-to-head on the two that are already on pharmacy shelves, see our semaglutide vs tirzepatide comparison. And if appetite quieting is the thing you actually care about, Jamey’s firsthand write-up lives on the retatrutide page, the other glucagon-hitting molecule in this class.

Frequently asked questions

Does survodutide work for weight loss?

Yes. In the phase 3 SYNCHRONIZE-1 trial, the 6.0 mg group lost an average of 13.0% of body weight at 76 weeks versus 5.4% with placebo (PubMed). SYNCHRONIZE-2 has also finished, but its results have not yet been posted (NCT06066528).

Is survodutide FDA-approved?

No. Survodutide is not FDA-approved and is not a supplement. It is an investigational drug in phase 3 trials, so the only legitimate access is through a registered study, not a pharmacy or an online vendor.

What’s the difference between survodutide and tirzepatide or retatrutide?

Survodutide is a GLP-1/glucagon dual agonist. Tirzepatide is GLP-1/GIP, and retatrutide is a GLP-1/GIP/glucagon triple agonist. Survodutide is the one that pairs GLP-1 with glucagon and no GIP, which is why it’s being studied heavily for fatty-liver disease.

What are survodutide’s side effects?

The most common survodutide side effects in trials were gastrointestinal — nausea, vomiting, diarrhea and constipation — usually mild to moderate and closely tied to how fast the dose was raised. Slower titration reduced them. Long-term and cardiovascular safety are still being tested.

Is survodutide banned in sport?

Effectively yes. Because survodutide has no regulatory approval for human use, it falls under WADA’s S0 “non-approved substances” category, which is prohibited at all times for athletes under anti-doping rules.

Who is survodutide for — and what to watch

Survodutide is, for now, a compound to follow rather than one to use: it is investigational, unapproved, and only legitimately available inside a clinical trial. The interest is well-earned — the glucagon-plus-GLP-1 design targets both appetite and liver fat, the phase 3 human data are real and positive, and it is one of the front-runners in the race to treat MASH. The honest limits: no approval, no validated at-home dose, and the long-term safety and cardiovascular outcomes still pending in phase 3. What to watch through 2026 and beyond is the SYNCHRONIZE obesity read-outs, the LIVERAGE fatty-liver results, and the cardiovascular-safety data — that’s the evidence that will move survodutide from promising to proven, or not. Anyone weighing the approved options today will find more settled answers on the GLP-1 & metabolic hub.